Breaking lupus research - September, 2014
Our September issue of UpdatesPlus Lupus is in production and now seems a good time to provide a brief insight into what we will be covering.
For the September issue we will analyze key events since the August edition including the advancement of Biogen Idec's lupus portfolio as the Phase 1 BIIB059 trials start. We take the opportunity to evaluate the mechanism of action of this candidate and assess its proof of concept.
We also highlight new preclinical data currently featured on our DailyUpdates-Inflammation channel supporting B7x as a novel drug target for lupus. This molecule is a new member of the B7 family; we provide background to B7x and analyze new research linking this to lupus. Again, relating to early stage R&D we will be looking at EMD Serono's collaboration with Mass General and what this may mean to lupus R&D.
September is usually a busy month for the drug development sector, with companies presenting investor updates and preparing for key conferences. We will be providing an analysis of information coming out of the Morgan Stanley Global Healthcare Conference and also preview ACR (coverage of this meeting forms part of our UpdatesPlus service). This is on top of our regular update of the Lupus pipeline and clinical timelines
This is by no means all that will be in the September issue, simply a taster of what will be included. To have a look at our August issue, to request notification of when the September issue is available or simply to find out more about our service please contact fiona.watts@leaddiscovery.co.uk
See UpdatesPlus-Lupus August issue
For the September issue we will analyze key events since the August edition including the advancement of Biogen Idec's lupus portfolio as the Phase 1 BIIB059 trials start. We take the opportunity to evaluate the mechanism of action of this candidate and assess its proof of concept.
We also highlight new preclinical data currently featured on our DailyUpdates-Inflammation channel supporting B7x as a novel drug target for lupus. This molecule is a new member of the B7 family; we provide background to B7x and analyze new research linking this to lupus. Again, relating to early stage R&D we will be looking at EMD Serono's collaboration with Mass General and what this may mean to lupus R&D.
September is usually a busy month for the drug development sector, with companies presenting investor updates and preparing for key conferences. We will be providing an analysis of information coming out of the Morgan Stanley Global Healthcare Conference and also preview ACR (coverage of this meeting forms part of our UpdatesPlus service). This is on top of our regular update of the Lupus pipeline and clinical timelines
This is by no means all that will be in the September issue, simply a taster of what will be included. To have a look at our August issue, to request notification of when the September issue is available or simply to find out more about our service please contact fiona.watts@leaddiscovery.co.uk
posted by Jon Goldhill at 10:46 AM
0 Comments:
Post a Comment
<< Home